1000802-50-5

Basic information

• Product Name: 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol
• Synonyms: 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol;3-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol;1H-Pyrazole-1-propanol, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
• CAS NO: 1000802-50-5
• Molecular Formula: C₁₂H₂₁BN₂O₃
• Molecular Weight: 252.12
• Mol File: 1000802-50-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 400.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• PKA: 14.91±0.10(Predicted)
• CAS DataBase Reference: 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol(1000802-50-5)
• EPA Substance Registry System: 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol(1000802-50-5)

Safety Data

• Hazardous Substances Data: 1000802-50-5(Hazardous Substances Data)

Upstream product

• 1309960-92-6 1-[3-(benzyloxy)propyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 925180-06-9 3-(4-bromo-1H-pyrazol-1-yl)propan-1-ol 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1380303-05-8 2-amino-N,N-diethyl-5-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]benzamide 
• 1380303-58-1 diethyl (4-{[4-({5-fluoro-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate 

Relevant articles and documents

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDINE-4-CARBOXAMIDES

Disclosed are sEH inhibitors of formula (I), wherein the variables are as defined herein, as well as pharmaceutical compositions, kits, and articles of manufacture that contain such compounds. Also disclosed are methods and intermediates for making the compounds and the use of such compounds to treat various disorders, diseases, and conditions associated with sEH.